Reviewing RadNet Inc. (RDNT)’s and DexCom Inc. (NASDAQ:DXCM)’s results

RadNet Inc. (NASDAQ:RDNT) and DexCom Inc. (NASDAQ:DXCM), are influenced by compare since they are both players in the Medical Laboratories & Research. These factors are particularly influence the analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation of the two firms.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
RadNet Inc. 953.49M 0.68 4.17M 0.19 64.97
DexCom Inc. 914.60M 14.69 43.20M 1.69 73.26

Table 1 demonstrates RadNet Inc. and DexCom Inc.’s gross revenue, earnings per share (EPS) and valuation. DexCom Inc. has lower revenue, but higher earnings than RadNet Inc. The company with the lower P/E out of the two companies is considered for more affordable of the two firms currently. RadNet Inc. is currently more affordable than DexCom Inc., because it’s trading at a lower P/E ratio.


Table 2 shows RadNet Inc. and DexCom Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
RadNet Inc. -0.44% -5.2% -0.5%
DexCom Inc. 4.72% 9.2% 4.4%

Risk & Volatility

RadNet Inc. has a beta of 0.54 and its 46.00% less volatile than S&P 500. From a competition point of view, DexCom Inc. has a 0.53 beta which is 47.00% less volatile compared to S&P 500.


The Current Ratio and Quick Ratio of RadNet Inc. are 1.1 and 1.1 respectively. Its competitor DexCom Inc.’s Current Ratio is 4.7 and its Quick Ratio is 4.4. DexCom Inc. can pay off short and long-term obligations better than RadNet Inc.

Analyst Ratings

RadNet Inc. and DexCom Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
RadNet Inc. 0 0 0 0.00
DexCom Inc. 0 4 5 2.56

DexCom Inc. on the other hand boasts of a $145.63 consensus target price and a -3.70% potential downside.

Institutional & Insider Ownership

RadNet Inc. and DexCom Inc. has shares owned by institutional investors as follows: 62.2% and 0%. Insiders owned roughly 6.2% of RadNet Inc.’s shares. Insiders Competitively, owned 1.6% of DexCom Inc. shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
RadNet Inc. -2.72% -16.68% -8.47% -3.91% 28.62% 24.16%
DexCom Inc. -4.74% -14.66% -14.95% 29.93% 105.85% 115.11%

For the past year RadNet Inc. was less bullish than DexCom Inc.


DexCom Inc. beats RadNet Inc. on 13 of the 14 factors.

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the imaging industry, including picture archiving communications systems; and provides teleradiology services for remote interpretation of images on behalf of radiology groups, hospitals, and imaging center customers. It owns and/or operates 305 outpatient imaging centers located in California, Maryland, Delaware, New Jersey, New York, and Rhode Island. The company was founded in 1981 and is headquartered in Los Angeles, California.

DexCom, Inc., a medical device company, together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. Its products include DexCom G4 PLATINUM system for continuous use by adults with diabetes; DexCom G4 PLATINUM with Share, a remote monitoring system; and DexCom G5 Mobile, a CGM system that directly communicates to a patientÂ’s mobile and its data can be integrated with DexCom CLARITY, which is a next generation cloud-based reporting software for personalized, easy-to-understand analysis of trends to improve diabetes management. The company also offers sensor augmented insulin pumps. It has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. The company was founded in 1999 and is headquartered in San Diego, California.